Publications by authors named "Johnny Raun"
Objective: Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).
Methods: Observational cohort study from the DANBIO registry.
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Ann Rheum Dis
November 2021
Article Synopsis
- In Denmark, a mandatory shift from the original adalimumab to two biosimilars, GP2017 (Hyrimoz) and SB5 (Imraldi), occurred in 2018, prompting a study to compare their effectiveness for treating rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
- An observational study using the DANBIO registry was conducted, analyzing treatment retention and remission rates through statistical methods, ultimately including 1318 patients who switched to either GP2017 or SB5.
- Results showed that GP2017 had a lower withdrawal risk and higher 6-month remission rates compared to SB5, although conclusions may be influenced by factors like differences in patient groups or variations in the
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Ann Rheum Dis
February 2019
Objectives: Real-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) in 2016. Clinical characteristics and treatment outcomes were studied in ETA-treated patients, who switched to SB4 (switchers) or maintained ETA (non-switchers).
View Article and Find Full Text PDFObjectives: In Denmark, patients with rheumatoid arthritis (RA) are registered in the nationwide clinical DANBIO quality register and the Danish National Patient Registry (DNPR). The aim was to study the validity of the RA diagnosis and to estimate the completeness of relevant RA cases in each registry.
Study Design And Setting: Patients registered for the first time in 2011 with a diagnosis of RA were identified in DANBIO and DNPR in January 2013.
Article Synopsis
- The study aimed to compare disease activity and treatment outcomes among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who are starting treatment with tumor necrosis factor inhibitors (TNFi), considering factors like HLA-B27 status.
- A total of 1,250 TNFi-naive patients were analyzed, revealing that nr-axSpA patients had higher baseline pain and fatigue scores but lower C-reactive protein levels and physical function compared to AS patients.
- While nr-axSpA patients had shorter median treatment adherence (1.59 years) than AS patients (3.67 years), response rates were similar across both groups, with
Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Rheumatology (Oxford)
December 2015
Objectives: To estimate the prevalence of Danish RA patients currently on biologic monotherapy and compare the effectiveness and drug adherence of biologic therapies applied as monotherapy.
Methods: All RA patients registered in the Danish biologics database (DANBIO) as receiving biologic DMARD (bDMARD) treatment as monotherapy without concomitant conventional synthetic DMARDs (csDMARDs) during the study period 1 May, 2011 through 30 April 2013 were eligible for inclusion. All patient files were checked to ensure that they were in accordance with the treatment registration in DANBIO.
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Ann Rheum Dis
May 2015
Objectives: To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.
Methods: In a double-blind, placebo-controlled trial, 85 disease-modifying antirheumatic drug-naïve patients with ERA were randomised to receive methotrexate, intra-articular glucocorticosteroid injections and placebo/adalimumab (43/42). Contrast-enhanced MRI of the right hand was performed at months 0, 6 and 12.
Objectives: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.
Methods: In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (<6 months duration) received methotrexate 7.